Core Viewpoint - Quantum BioPharma Ltd. has successfully closed a non-brokered private placement, issuing 30 Class A Multiple Voting Shares at a price of $25 each, resulting in gross proceeds of $750 million [1][2]. Offering Details - The securities issued are subject to a statutory hold period of four months plus a day from issuance as per Canadian securities laws [2]. - Proceeds from the offering will be utilized for general working capital purposes [2]. Related Party Transactions - Xorax Family Trust and Fortius Research and Trading Corp., both associated with company insiders, purchased all Class A Multiple Voting Shares in the offering, qualifying as a related-party transaction under MI 61-101 [3]. - The company has relied on exemptions from formal valuation and minority shareholder approval requirements as the transaction did not exceed 25% of the company's market capitalization [3]. Corporate Update - The company has terminated its at-the-market offering agreement with H.C. Wainwright & Co., effective December 6, 2025, with the termination taking effect on December 20, 2025 [16]. - No Class B Subordinate Voting Shares have been sold under the previous sales agreement, which allowed for the sale of up to $21.225 million worth of shares [17]. Debt Settlement - Quantum BioPharma has settled $260,000 owed to an arm's length creditor by issuing 17,626 Class B Subordinate Voting Shares at a deemed price of $14.75 per share [18]. Company Overview - Quantum BioPharma focuses on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at preventing myelin degradation associated with multiple sclerosis [19]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until reaching $250 million, after which the royalty will drop to 3% [19].